In ~15-20% of patients, myasthenic crisis may be the initial presentation of myasthenia. In addition, inactivation of pyruvate dehydrogenase E11 (Pdha1), a subunit of the pyruvate dehydrogenase complex that converts pyruvate to acetyl-CoA in the tricarboxylic acid cycle in mitochondria, was shown to significantly suppress Pten loss-driven prostate tumorigenesis through suppression of lipid biosynthesis (Bezzi et al. She has received several awards, including the Evergreen Fund 2014; Azad et al. Locus Biosciences delivered the treatment directly to the bladder by catheter in the phase 1 trial, and plans to develop an oral or IV treatment for later phases. This treatment can be used to treat both beta thalassemia and SCD. He holds full faculty privileges in Immunology in Mayo Clinic Graduate School of Biomedical Sciences. Regulation of cancer cell migration and bone metastasis by RANKL, Regulatory T cells: mechanisms of differentiation and function. basics. 2011; Wang et al. Success in this trial would be a major step forward in genetic medicine. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, et al. Mortgaging his house and receiving a loan from Western Economic Diversification, Eaves was able to build a clean room and STEMCELL Technologies Inc. was born on July 2, 1993. 3. But will unwanted DNA changes have meaningful effects on patients down the line or when given to larger cohorts? 2016). Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. 3. 2011. 2007. 2005. Your doctor may recommend a different schedule based on your overall health. Doctors currently believe that too much exposure to ultraviolet light either from sun exposure or tanning beds is the leading cause. 2017; Wan et al. Such investments will illuminate the key genetic events and effective therapeutic combinations for the molecular subsets encountered in the clinic. Zhu S, Zhao D, Yan L, Jiang W, Kim JS, Gu B, Liu Q, Wang R, Xia B, Zhao JC, et al. Similarly, AR-dependent hormone-nave metastatic tumors initially respond to ADT and then progress to mCRPC. Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, et al. 2014. Melanomas have jagged or uneven borders. 1. Here, we showcase the use of LIONESS in combination with SCORPION for the generation of individual-cell gene regulatory networks from single-cell RNA-seq data. In addition, CpG-STAT3 siRNA conjugates targeting TLR9+ granulocytic MDSCs efficiently abrogated the immunosuppressive activity of MDSCs isolated from prostate cancer patients (Hossain et al. Alternative Dosing Strategies for Immune Checkpoint Inhibitors From IHC biochemistry basics to identifying biomarkers, this text provides a comprehensive view of diagnostic IHC in a reader-friendly format. Find out what the stages mean for prognosis and survival rates. 2013. 2010. Privacy issues and ethical dilemmas could decelerate AI-based advancements in cancer research. 2010; Barbieri et al. MDSCs and TAMs are powerfully immunosuppressive (Fig. The National Institutes of Health (NIH) recommends no more than 3 grams (3,000 mg) of combined EPA and DHA per day. 1. This is particularly a concern with CRISPR treatments delivered by viruses, since the genome-editing components may persist in the cell for a long time, giving them more opportunity to make editing errors. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, et al. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, et al. In addition, plasmocytes expressing immunoglobulin A, IL-10, and PD-L1 have been identified as the immunosuppressive B cells directly involved in this process. 2010). 2012; Hieronymus and Sawyers 2012; The Cancer Genome Atlas Research Network 2015). The clinical impact of the observed data disparity needs to be studied to overcome this major barrier in solving cancer genomics disparities in ancestrally African patients. The most common prostate cancer genomic alterations are translocations involving androgen-regulated promoters and the ETS family of transcription factors, such as ERG and the ETV genes (Sizemore et al. Our systems and components help people working in clinical diagnostics, basic and translational research and drug discovery bring their science to life. Cancer Immunotherapy Treatment: How a Mediterranean Diet Can Help, Melanoma: New Potential Treatment Using Immune Cells is Announced. 2017. This causes sudden, severe pain. The immune system is highly regulated to avoid attacking healthy cells. 2015), and Myc activation in combination with Pten loss drives genomic instability and metastatic prostate cancer (Hubbard et al. More Medical CRISPR Firsts To Look Out For, directly repair the mutation that causes SCD. Some T cell receptors work as checkpoints that determine whether an immune response occurs. hATTR is a rare disease, affecting about 50,000 people worldwide. Adoptive cell therapy (ACT) is a promising immunotherapy treatment option that uses genetically modified immune cells (T cells) to eliminate tumors. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. These factors include the size, location, and type of tumor. 2017). 2017. Additionally, his lab aims to understand the role of these molecular targets in the development and progression of normal cells transforming into cancer cells of the pancreas. Several large-scale genomic studies in both primary prostate tumors and mCRPC have identified recurrent DNA copy number changes, mutations, rearrangements, and gene fusions (Table 1; Taylor et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells, Modeling disease in vivo with CRISPR/Cas9. (2) Castration resistance. OA can affect any joint in the body, but it most often affects the: As OA progresses, it can begin to cause symptoms other than stiffness. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population, History of myeloid-derived suppressor cells. Locus Biosciences delivered the treatment directly to the bladder by catheter in the phase 1 trial, and plans to develop an oral or IV treatment for later phases. 2. Review tools for efficient cDNA preparation. This can lead to fluid buildup and swelling in your limbs, called lymphedema. checkpoint inhibitor induced myasthenia gravis, Dangayach N, Classen J, O'Phelan K(2022), Checkpoint inhibitor induced myasthenia gravis, Five pearls for the dyspneic patient with GBS or MG, Myasthenia Gravis: Background information. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, et al. In this article, we will go over the basics of clinical trials and then map out the current CRISPR-based trials from disease background to what we really hope to learn from these trials. 2017a. The PSA(/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration, Microenvironmental regulation of tumor progression and metastasis. 2016a. 2014). Many organizations provide professional and supportive services when youve been diagnosed with melanoma. When you attend the event remember to use the hashtag #LRcancer to follow the conversation and connect with other members of the global Cancer & Oncology Research community! This patient, Victoria Gray, has shown remarkable progress. (2020). 2015. In addition to the natural action of phages that kills bacteria, these bacteriophages contain CRISPR-Cas3 in their genome. Recurrent genetic alterations of key components in the TGF-/SMAD4 pathway have been found in CRPC genomics (Grasso et al. G.W. Roven BH, et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. In CRPC patients treated with combined prostate GVAX/ipilimumab immunotherapy, high numbers of M-MDSCs before treatment correlated with worse overall survival (Santegoets et al. 1. 2017). In addition to traditional treatments, your doctor will recommend palliative therapy. 3. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. 2017; Mu et al. 2005). Our rigorous testing protocols go above and beyond what the average user would ever encounter and our quality control measures exceed industry standards. There are known outcome disparities between Black and White patients with pancreatic neuroendocrine tumors (pNETs). Primary, adaptive, and acquired resistance to cancer immunotherapy, Molecular genetics of prostate cancer: new prospects for old challenges. The potent AR antagonists enzalutamide and apalutamide can increase the survival of patients with mCRPC (Scher et al. 2017) and future clinical trials will allow us to test the efficacy of agents targeting the DNA damage repair pathways in combinations with other therapies. By simplifying workflows and expanding assay menus, we are broadening access to genomic data and lowering barriers to routine use. 2016). Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J. The ETS family of oncogenic transcription factors in solid tumours. 2016), and insulin and keratinocyte growth factor (Culig 2004; Zhang et al. Thus, Dr. Bruno's overall research objective is to develop a B cell-specific immunotherapy in the next five to ten years. These MDSCs possess potent immunosuppressive activity, play a major role in the suppression of immune responses in cancer through a variety of mechanisms (Gabrilovich and Nagaraj 2009), and have been implicated in the promotion of angiogenesis, tumor cell invasion, and metastases (Yang et al. 2016b; Zaretsky et al. There isnt a cure, but treatments effectively reduce and control symptoms. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna, its first in vitro diagnostic product for prognosis of early stage breast cancer. If you have metastatic melanoma, you may experience symptoms such as: Melanoma occurs due to a mutation in melanin-producing skin cells. (2021). 2017. But, unwanted changes at the target site were observed frequently, with 70% of cells showing at least one mutation at or near the target site during manufacturing. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, et al. The metabolic transcriptional coactivator peroxisome proliferator-activated receptor coactivator 1 (PGC1) was shown to induce a catabolic state and suppress prostate cancer metastasis through activation of an estrogen-related receptor (ERR)-dependent transcriptional program, as genetic inactivation of Pgc1a in Pten-deficient prostate tumors results in an increase in metastasis (Torrano et al. 2; Litwin and Tan 2017). Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. The speakers below have been approved for Continuing Education Credits. The advent of CRISPR technology opens up new possibilities in precision medicine. Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, et al. 2015. He earned his Ph.D. in Physiology and Pharmacology from the University of Georgia and completed two postdoctoral fellowships in immunology, one at the University of British Columbia and the other at the University of Washington. 1. Lukacs RU, Memarzadeh S, Wu H, Witte ON. The new PMC design is here! 2017), MDSCs (Lu et al. 2014. Deterioration may occur in about half of patients. Use tools and resources within COSMIC to bring actionable meaning to genomic data, such as the identification of driver mutations, functional biological consequences, and clinically significant somatic variants, which can aid diagnostics and treatment decisions. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. 2010. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics. Osteoarthritis (OA) is a form of degenerative joint pain. To characterize the subclonal architecture of mCRPC, Gundem et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. 2002) and castration resistance (Xu et al. In addition, Myc functions as a driver in the metastatic Pten/Trp53-deficient RapidCaP GEMM (Nowak et al. As the cell tries to repair the DNA without a corrected template, the repair attempts mutate the gene even. 2009. Fujii T, Shimada K, Asai O, Tanaka N, Fujimoto K, Hirao K, Konishi N. 2013. 2001. 2014), and dendritic cell vaccination (Laborde et al. (2016, January 28). 2007. Future multi-omic pNET analyses must be powered to investigate the biologic source of these disparities further. Then, they put them back into the patients bloodstream by IV. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications Notably, prostate-specific transgene expression of the truncated human ERG yields only minimal or weak PIN in GEMMs (Tomlins et al. These therapies include: Read more: Alternative treatments for melanoma . Caris Precision Oncology Alliance (POA) is a vivid example of how this large network takes advantage of collaboration and understanding the nuances of molecular profiling to scale up the research operations that eventually can help all patients diagnosed with cancer. 2015). Additionally, immunotherapy (immuno-oncology), a newer treatment option, uses checkpoint inhibitors such as Keytruda (pembrolizumab) to boost the immune response against cancer cells. We use electronic health records (EHR) data to 1) assess the temporal trends in treatment decisions and patient outcomes; and 2) emulate a randomized controlled trial (RCT) using EHR with temporal trends properly adjusted. Our website services, content, and products are for informational purposes only. 1995. Research into in vivo approaches, which could eliminate the need for chemotherapy and decrease the associated risks and expenses, is in early stages, but will be a focus of those working to make more widely accessible CRISPR-based therapies for blood disorders in the coming years. Common genetic aberrations in prostate cancers and their biological functions. Therapeutic advances in oncology have been shaped by a detailed catalog of genotypic variations between patients that informs responses to targeted treatments (Bedard et al. The stiffness can also be more severe and impact your mobility. He currently has three FDA-approved vaccine trials underway and is principal investigator of 3 Department of Defense grants to test vaccines aimed at preventing recurrence breast cancer, including triple negative breast cancer for which there are no targeted therapies. TTR is primarily made in the liver, so researchers are taking advantage of this tendency to naturally get the treatment to where it is needed. Gout is a type of arthritis. Recognized as one of the fastest growing life science companies, BioLegend transforms the boundaries of innovation for basic science and medical researchers world-wide. Unfortunately, the PSA test is unreliable for detecting high-grade PCa (HGPC), leaving a gap for accurate HGPC diagnoses. Currently, Dr Baines studies the functional significance of the oncogenic Pim kinase family in pancreatic cancer growth and development. degrees in Biological Sciences from Humboldt University in Berlin, Germany. He currently has three FDA-approved vaccine trials underway and is principal investigator of 3 Department of Defense grants to test vaccines aimed at preventing recurrence breast cancer, including triple negative breast cancer for which there are no targeted therapies. Using this approach, we generated 54,798 transcriptome-wide individual-cell gene regulatory networks for MDA-MB-231 cells carrying a random subset of gRNAs from a library containing 20,139 sgRNAs targeting non-coding regions of the human genome. 2014. To bridge this gap, a Laboratory Information Management System (LIMS) plays a critical role. This talk covers the scientific rational for PSMA PET and targeted radionuclide therapy and what to expect on the day of therapy. involving diaphragm and limbs). IDH1 and IDH2 mutations have been associated with a DNA methylation phenotype in other cancer types (Figueroa et al. 2016b. 2016. Her research focuses on improving T cell immunotherapy, which uses immune cells to target and destroy cancer cells. Interestingly, 4-abiraterone (D4A), an abiraterone metabolite, inhibits multiple enzymes involved in DHT synthesis such as CYP17A1, 3HSD, and SRD5A and displays a more potent anti-tumor activity than abiraterone, suggesting treatment with D4A as a more clinically effective therapeutic approach than treatment with abiraterone (Li et al. Warm joints, or the sensation of heat or warmth around the joints, can be caused by arthritis, bursitis, osteoarthritis, tennis elbow and other. It affects the skin cells that produce melanin, the pigment that colors your skin. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, Bastholt L, et al. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. (2021). Test is cheap, safe, noninvasive and surprisingly sensitive (~90%) and specific (~80%). Efficiency meaning, what percentage of cells are edited is a big question. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Integrative clinical genomics of advanced prostate cancer. 1. 2013; Schumacher and Schreiber 2015; Ruella et al. Growth factors secreted by prostate cancer cells, including endothelin 1 (ET-1), adrenomedullin, fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), and bone morphogenetic proteins (BMPs), can stimulate osteoblast activation to form new bone via paracrine signaling (Logothetis and Lin 2005; Guise et al. 2015), but, most recently, this finding was refuted by Shoag et al. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P. 2010. 2005), also shows promising clinical activity in cancers possessing mutations in other DNA repair genes (Lord and Ashworth 2016). 2014; Henzler et al. COSMIC, the Catalogue of Somatic Mutations in Cancer, was established nearly 20 years ago, and has been a gold-standard resource for this data ever since. AR splicing variants (e.g., AR-V7) have drawn intense interest as a liquid biopsy prognostic biomarker for predicting therapy resistance. Castration also induced the expression of colony-stimulating factor 1 (Csf1) in prostate cancer cells to attract macrophages to promote the survival of prostate cancer cells. In particular, we develop, produce Careers, This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see, prostate cancer, therapy resistance, tumor microenvironment, {"type":"clinical-trial","attrs":{"text":"NCT02012296","term_id":"NCT02012296"}}, {"type":"clinical-trial","attrs":{"text":"NCT02643667","term_id":"NCT02643667"}}, {"type":"clinical-trial","attrs":{"text":"NCT03177460","term_id":"NCT03177460"}}, {"type":"clinical-trial","attrs":{"text":"NCT02452424","term_id":"NCT02452424"}}, {"type":"clinical-trial","attrs":{"text":"NCT02777710","term_id":"NCT02777710"}}, {"type":"clinical-trial","attrs":{"text":"NCT02880371","term_id":"NCT02880371"}}, {"type":"clinical-trial","attrs":{"text":"NCT01972217","term_id":"NCT01972217"}}, {"type":"clinical-trial","attrs":{"text":"NCT02711956","term_id":"NCT02711956"}}, {"type":"clinical-trial","attrs":{"text":"NCT02607228","term_id":"NCT02607228"}}, {"type":"clinical-trial","attrs":{"text":"NCT02861573","term_id":"NCT02861573"}}, {"type":"clinical-trial","attrs":{"text":"NCT03016312","term_id":"NCT03016312"}}, {"type":"clinical-trial","attrs":{"text":"NCT01799278","term_id":"NCT01799278"}}, {"type":"clinical-trial","attrs":{"text":"NCT02833883","term_id":"NCT02833883"}}, {"type":"clinical-trial","attrs":{"text":"NCT02484404","term_id":"NCT02484404"}}, {"type":"clinical-trial","attrs":{"text":"NCT02649855","term_id":"NCT02649855"}}, {"type":"clinical-trial","attrs":{"text":"NCT02933255","term_id":"NCT02933255"}}, {"type":"clinical-trial","attrs":{"text":"NCT02506114","term_id":"NCT02506114"}}, {"type":"clinical-trial","attrs":{"text":"NCT02814669","term_id":"NCT02814669"}}, {"type":"clinical-trial","attrs":{"text":"NCT02463799","term_id":"NCT02463799"}}. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. Expansion of myeloid immune suppressor Gr. 2002. The human and mouse prostates exhibit anatomic differences as well as cellular similarities (Fig. After 10 years, he became a tenured Professor at Duke University Medical Center in North Carolina. STEMCELL Technologies was launched in 1993 when founder and CEO Allen Eaves needed a way to meet the increasing demands for his standardized, cost-effective cell culture media for growing blood-forming stem cells. 2017). Tumour exosome integrins determine organotropic metastasis. Longitudinal sampling and comprehensive genomic and pathologic analyses of a patient with prostate cancer revealed that the lethal metastatic clone arose from a small low-grade primary tumor focus harboring PTEN and TP53 alterations rather than the bulk higher-grade primary cancer or a lymph node metastatic focus (Haffner et al. Getting the treatments where they need to be, and only where they need to be, is one of the biggest challenges of CRISPR-based therapies. Let's look at the reason why and how to prevent melanoma when you have NHL. Phase 1/2 trials of enzalutamide in combination with BET domain protein inhibitors (ZEN003694 and GS-5829) are currently under way to target the BRD4 and AR cross-talk in mCRPC ({"type":"clinical-trial","attrs":{"text":"NCT02711956","term_id":"NCT02711956"}}NCT02711956 and {"type":"clinical-trial","attrs":{"text":"NCT02607228","term_id":"NCT02607228"}}NCT02607228). Don't intubate patients based on arbitrary cutoff values in pulmonary mechanics (there's zero data to support this practice). There isn't much evidence on this (with available literature nicely reviewed by Prado et al.). In addition, AR genomic structural rearrangements were present in one-third of mCRPC tumors, resulting in aberrant expression of diverse AR variant species lacking the ligand-binding domain and resulting in persistent activation of AR signaling, such as AR variant 7 (AR-V7), which appears to drive disease progression (Antonarakis et al. Many of these prostate cancer GEMMs use the ARR2PB promoter to drive prostate-specific expression of Cre recombinase and transgenes encoding oncogenes (Wu et al. In LCA10, the mutation in a photoreceptor gene means cells make a shortened, defective version of a crucial protein. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy, Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Additionally, three groups (Dai et al. Explain how fusion proteins can improve T cell therapy. The inability of clinical or pathologic parameters (PSA levels, TNM stage, and Gleason score) to accurately distinguish the few aggressive cancers from the many indolent cancers remains at the center of the overtreatment problem involving radical prostatectomy and radiation therapy. This may include radiation therapy to help reduce pain. He is also recognized as the 2017 Investigator of the Year at the Mayo Clinic campus in Florida. Following this, Dr Myositis or Miller-Fisher variant of Guillain-Barre syndrome may present with prominent ocular/bulbar symptoms. 1. 2008. 2017). Over time, it can also cause joint deformity and bone erosion. Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, Le Magnen C, Chester D, Mostaghel EA, Califano A, et al. It is also the first trial to deliver genome-editing components systemically, meaning to the whole body rather than to one specific type of cell or tissue. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, et al. 2018). [Fact sheet]. Pyridostigmine starting 30 mg TID and up-titrating to a maximum of 120 mg QID as tolerated. Prostate cancer (PCa) affects one in nine men and is the most diagnosed solid tumor cancer among men in the United States. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, et al. 2005; Taylor et al. HHS Vulnerability Disclosure, Help De Laere B, van Dam PJ, Whitington T, Mayrhofer M, Diaz EH, Van den Eynden G, Vandebroek J, Del-Favero J, Van Laere S, Dirix L, et al. 2020 was a big year for CRISPR the discoveries of new Cas proteins, use of CRISPR technology to study and develop diagnostic tests of COVID-19, a Nobel Prize, and more. Many treatments in development use viruses to deliver the genome-editing components. These lymph nodes are then removed and screened for cancer cells. DNMT1 has been shown to act as a tumor suppressor gene in early stage prostate cancer and an oncogene in late stage prostate cancer (Kinney et al. Keep reading to learn more about possible causes and treatments. Find a melanoma support group. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. As PDX models require significant resources for establishment and characterization, the National Cancer Institute repository of patient-derived models (PDMs) comprised of PDXs and in vitro patient-derived cell cultures should provide researchers increased access to a diversity of human models. Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren SK, Badani KK, McKiernan JM, Benson MC, Hibshoosh H, et al. The people of Baker have built that reputation by taking no chances with customers' safety and making no compromises when it comes to protecting the success of your research. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Currently, effective treatment of patients with uLMS remains challenging due to our limited understanding of the molecular mechanisms driving uLMS. EMCrit is a trademark of Metasin LLC. NF-B regulates androgen receptor expression and prostate cancer growth.